中国循证医学杂志

中国循证医学杂志

2016~2017 年中国肝癌临床实践指南的质量评价

查看全文

目的 采用 AGREE Ⅱ工具评价 2016~2017 年发表的中国肝癌临床实践指南的质量。 方法 计算机检索 CNKI、WanFang Data、CBM 和 VIP 数据库,搜集我国制定的肝癌临床实践指南,检索时限为 2016 年 1 月 1 日至 2018 年 1 月 1 日。由 4 位评价员按照纳入与排除标准独立筛选文献和提取资料,采用 AGREE Ⅱ 评价纳入中国肝癌指南的质量。 结果 共纳入 7 部指南。AGREE Ⅱ各领域平均得分如下:范围和目的为 65.1%,参与人员为 39.4%,制定严谨性为 64.3%,清晰性为 55.6%,应用性为 61.8%,编辑独立性为 6.1%。 结论 我国肝癌临床实践指南质量较高,尤其是其推荐指导意见对临床具有较大实用价值,但与国外同类指南相比,在某些方面还有待提高。

Objectives To assess the quality of clinical practice guidelines for primary hepatic carcinoma published in 2016 and 2017 in China. Methods CNKI, WanFang Data, CBM and VIP databases were searched for clinical practice guidelines for primary hepatic carcinoma in China. The search date was from Jan. 1st, 2016 to Jan. 1st, 2018. Four researchers independently selected literatures and extracted data according to the inclusion and exclusion criteria. The Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ) was utilized to assess the methodological quality of the guidelines. Results A total of 7 guidelines were included. The average scores of six domains for these guidelines were: 65.1% for scope and purpose, 39.4% for stakeholders’ involvement, 64.3% for rigor of development, 55.6% for clarity of presentation, 61.8% for applicability and 6.1% for editorial independence. Conclusions The quality of clinical practice guidelines for primary hepatic carcinoma in China is relative high, of which the recommendations are of great value in clinical practice, yet still required to be improved in some ways.

关键词: 原发性肝癌; 临床实践指南; 共识; 质量评价; AGREE Ⅱ

Key words: Primary hepatic carcinoma; Clinical practice guideline; Consensus; Quality assessment; AGREE Ⅱ

引用本文: 李琴, 刘非, 魏永刚, 李波. 2016~2017 年中国肝癌临床实践指南的质量评价. 中国循证医学杂志, 2018, 18(10): 1109-1113. doi: 10.7507/1672-2531.201804143 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (Baltimore, Md), 2013, 58(1): 98-107.
2. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol, 2012, 56(6): 1330-1335.
3. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol, 2012, 107(4): 569-577.
4. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol, 2012, 57(4): 821-829.
5. 陈丹丹, 刘媛, 姬旭慧, 等. 原发性肝癌发病影响因素的病例对照研究. 郑州大学学报 (医学版), 2013, 48(2): 249-253.
6. 相迪, 戴建国. 原发性肝癌的综合治疗研究进展. 山东医药, 2017, 57(20): 111-112.
7. Graham R, Mancher M, Miller Wolman D, et al. Clinical Practice Guidelines We Can Trust. Port J Nephrol Hypert, 2011: 1-13.
8. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J, 2010, 182(18): E839-E842.
9. 谢利民, 王文岳. 《临床指南研究与评价系统Ⅱ》简介. 中西医结合学报, 2012, 10(2): 160-165.
10. 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范 (2017 年版). 中华消化外科杂志, 2017, 16(7): 635-647.
11. 高春芳, 房萌, 季君, 等. 多学科甲胎蛋白异质体临床应用专家共识. 诊断学理论与实践, 2018, 17(1): 19-24.
12. 程树群, 杨甲梅, 沈锋, 等. 肝细胞癌合并门静脉癌栓多学科诊治——东方肝胆外科医院专家共识. 中华肝胆外科杂志, 2015, 21(9): 582-590.
13. 郑加生, 范卫君, 胡凯文, 等. 影像引导肝脏肿瘤热消融治疗技术临床规范化应用专家共识. 临床肝胆病杂志, 2017, 33(10): 1864-1869.
14. 中华医学会放射肿瘤学分会, 中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会, 中国研究型医院学会放射肿瘤学分会肝癌学组. 2016 年原发性肝癌放疗共识. 中华放射肿瘤学杂志, 2016, (11): 1141-1150.
15. 陈亚进, 曹军. 肝脏及胆道恶性肿瘤多学科综合治疗协作组诊疗模式专家共识. 中国实用外科杂志, 2017, 33(10): 1864-1869.
16. 中国医师协会介入医师分会. 注射用洛铂在原发性肝癌 TACE 治疗中的专家共识 (2016 版). 中华介入放射学电子杂志, 2016, 4(1): 1-3.
17. 陈辉, 范卫君, 胡凯文, 等. 基于 AGREE Ⅱ的阑尾炎临床实践指南质量评价研究. 重庆医科大学学报, 2015, 40(10): 1280-1284.
18. 江梅, 廖理粤, 罗炜, 等. 国内咳嗽诊疗指南的质量评价. 中国循证医学杂志, 2015, 15(4): 409-413.
19. 李楠, 姚亮, 吴琼芳, 等. 2012~2013 年中国大陆期刊发表临床实践指南质量评价. 中国循证医学杂志, 2015, 15(3): 259-263.
20. EASL Clinical Practice Guidelines:. Management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
21. 张鸣明, 刘鸣. 循证医学的概念和起源. 华西医学, 1998, 13(3): 265.
22. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ, 1996, 312(7023): 71-72.
23. Chow PK, Choo SP, Ng DC, et al. National cancer centre singapore consensus guidelines for hepatocellular carcinoma. Liver Cancer, 2016, 5(2): 97-106.
24. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11(4): 1-54.
25. Ahn JH, An C, Choi JY, et al. Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the Korean society of abdominal radiology. Korean J Radiol, 2017, 18(3): 427-443.
26. Cheung TT, Han HS, She WH, et al. The Asia pacific consensus statement on laparoscopic liver resection for hepatocellular carcinoma: a report from the 7th Asia-pacific primary liver cancer expert meeting held in Hongkong. Liver Cancer, 2018, 7(1): 28-39.
27. Heimbach J, Kulik L M, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2017, 67(1): 358-380.